Squarepoint
SYRE icon

Squarepoint’s Spyre Therapeutics SYRE Stock Holding History

Squarepoint’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,232
Closed -$339K – 4879
2025
Q3 		$339K Sell
20,232
-9,814
-33% -$160K ﹤0.01% 3572
2025
Q2 		$450K Sell
30,046
-41,965
-58% -$621K ﹤0.01% 3363
2025
Q1 		$1.16M Buy
72,011
+56,780
+373% +$1.18M ﹤0.01% 2528
2024
Q4 		$355K Buy
15,231
+6,754
+80% +$198K ﹤0.01% 4036
2024
Q3 		$249K Buy
+8,477
New +$236K ﹤0.01% 3568
2024
Q2 		– Sell
-8,161
Closed -$310K – 4635
2024
Q1 		$310K Buy
+8,161
New +$236K ﹤0.01% 3357
2020
Q4 		– Sell
-1,608
Closed -$285K – 3252
2020
Q3 		$285K Buy
1,608
+56
+4% +$10.4K ﹤0.01% 1837
2020
Q2 		$359K Buy
1,552
+601
+63% +$114K 0.01% 1492
2020
Q1 		$111K Sell
951
-978
-51% -$166K ﹤0.01% 1620
2019
Q4 		$368K Sell
1,929
-905
-32% -$178K ﹤0.01% 1931
2019
Q3 		$545K Buy
2,834
+719
+34% +$140K ﹤0.01% 1574
2019
Q2 		$362K Buy
2,115
+565
+36% +$97.7K ﹤0.01% 1845
2019
Q1 		$312K Sell
1,550
-828
-35% -$173K ﹤0.01% 1751
2018
Q4 		$445K Sell
2,378
-482
-17% -$102K 0.01% 1312
2018
Q3 		$684K Buy
2,860
+1,536
+116% +$359K 0.01% 1166
2018
Q2 		$350K Buy
1,324
+900
+212% +$221K ﹤0.01% 1323
2018
Q1 		$105K Buy
+424
New +$76.6K ﹤0.01% 1567
2017
Q2 		– Sell
-488
Closed -$91K – 1799
2017
Q1 		$91K Buy
+488
New +$68.9K ﹤0.01% 1424

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Squarepoint's SYRE Position: Q4 2025 in Review

Squarepoint sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 20,232 shares — an estimated $339K sold.

Squarepoint first reported a position in SYRE in Q1 2017 and held it in 18 quarters. The position peaked at $1.16M in Q1 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Squarepoint reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 20,232 Spyre Therapeutics shares in Q4 2025, an estimated $339K.
  • Squarepoint first reported a position in Spyre Therapeutics in Q1 2017 and held it in 18 quarters.
  • Squarepoint's Spyre Therapeutics position peaked at $1.16M in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.